Michael M Hopkins
Michael M Hopkins
Professor of Innovation Management, SPRU, University of Sussex Business School
Verified email at
Cited by
Cited by
The myth of the biotech revolution: An assessment of technological, clinical and organisational change
MM Hopkins, PA Martin, P Nightingale, A Kraft, S Mahdi
Research policy 36 (4), 566-589, 2007
Big Pharma, little science?: A bibliometric perspective on Big Pharma's R&D decline
I Rafols, MM Hopkins, J Hoekman, J Siepel, A O'Hare, ...
Technological forecasting and social change 81, 22-38, 2014
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe
ME van den Akker-van Marle, D Gurwitz, SB Detmar, CM Enzing, ...
Pharmacogenomics 7 (5), 783-792, 2006
Putting pharmacogenetics into practice
MM Hopkins, D Ibarreta, S Gaisser, CM Enzing, J Ryan, PA Martin, ...
Nature biotechnology 24 (4), 403-410, 2006
From funding gaps to thin markets: UK government support for early-stage venture capital
P Nightingale, G Murray, M Cowling, C Baden-Fuller, C Mason, J Siepel, ...
National Endowment for Science, Technology and the Arts, 2009
The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies
A Woelderink, D Ibarreta, MM Hopkins, E Rodriguez-Cerezo
The pharmacogenomics journal 6 (1), 3-7, 2006
Strategic intelligence on emerging technologies: Scientometric overlay mapping
D Rotolo, I Rafols, MM Hopkins, L Leydesdorff
Journal of the Association for Information Science and Technology 68 (1 …, 2017
Funding data from publication acknowledgments: Coverage, uses, and limitations
N Grassano, D Rotolo, J Hutton, F Lang, MM Hopkins
Journal of the Association for Information Science and Technology 68 (4 …, 2017
Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980–2009
MM Hopkins, PA Crane, P Nightingale, C Baden-Fuller
Industrial and Corporate Change 22 (4), 903-952, 2013
Pharmacogenetics in Europe: barriers and opportunities
D Gurwitz, E Zika, MM Hopkins, S Gaisser, D Ibarreta
Public Health Genomics 12 (3), 134-141, 2009
Generative and degenerative interactions: positive and negative dynamics of open, user‐centric innovation in technology and engineering consultancies
MM Hopkins, J Tidd, P Nightingale, R Miller
R&d Management 41 (1), 44-60, 2011
A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA
S Hogarth, MM Hopkins, V Rodriguez
Sociology of health & illness 34 (2), 234-250, 2012
The hidden research system: The evolution of cytogenetic testing in the national health service
MM Hopkins
Science as Culture 15 (3), 253-276, 2006
DNA patenting: the end of an era?
MM Hopkins, S Mahdi, P Patel, SM Thomas
Nature biotechnology 25 (2), 185-187, 2007
Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK
MM Hopkins, P Nightingale
Research policy 35 (3), 355-374, 2006
Towards a method for evaluating technological expectations: Revealing uncertainty in gene silencing technology discourse
JJ Sung, MM Hopkins
Technology Analysis & Strategic Management 18 (3-4), 345-359, 2006
Projects, project capabilities and project organizations
P Nightingale, C Baden-Fuller, MM Hopkins
Project-based organizing and strategic management, 215-234, 2011
Science, the State and the City: Britain's Struggle to Succeed in Biotechnology
G Owen, MM Hopkins
Oxford University Press, 2016
Shares in the human genome—the future of patenting DNA
SM Thomas, MM Hopkins, M Brady
nature biotechnology 20 (12), 1185-1188, 2002
The phantom menace of gene patents
S Gaisser, MM Hopkins, K Liddell, E Zika, D Ibarreta
Nature 458 (7237), 407-408, 2009
The system can't perform the operation now. Try again later.
Articles 1–20